Cargando…
Improving Outcomes After Relapse in Ewing's Sarcoma: Analysis of 114 Patients From a Single Institution
The outcome for patients with relapsed Ewing's sarcoma is poor. A retrospective analysis was carried out to identify factors associated with improved survival. Between 1992 and 2002, 114 patients presented with relapsed or progressive disease. Median time to progression/relapse was 13 months (r...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1698143/ https://www.ncbi.nlm.nih.gov/pubmed/17496997 http://dx.doi.org/10.1155/SRCM/2006/83548 |
_version_ | 1782131227313045504 |
---|---|
author | McTiernan, Anne M. Cassoni, Anna M. Driver, Deirdre Michelagnoli, Maria P. Kilby, Anne M. Whelan, Jeremy S. |
author_facet | McTiernan, Anne M. Cassoni, Anna M. Driver, Deirdre Michelagnoli, Maria P. Kilby, Anne M. Whelan, Jeremy S. |
author_sort | McTiernan, Anne M. |
collection | PubMed |
description | The outcome for patients with relapsed Ewing's sarcoma is poor. A retrospective analysis was carried out to identify factors associated with improved survival. Between 1992 and 2002, 114 patients presented with relapsed or progressive disease. Median time to progression/relapse was 13 months (range, 2–128). Treatment at relapse included high dose treatment (HDT) in 29 patients, and surgery or definitive radiotherapy in 29. 2 and 5-year post relapse survival (PRS) was 23.5% and 15.2%, respectively. In multivariate analysis, the most significant factors associated with improved survival were disease confined locally or to the lungs (2-year PRS, 40% versus 6%; P < .001), relapse > 18 months from diagnosis (2-year PRS, 53% versus 8%; P < .001), HDT at relapse (2-year PRS, 62% versus 11%; P < .001), and surgery and/or radiotherapy at relapse (2-year PRS, 51% versus 14%; P < .001). First treatment failure in Ewing's sarcoma is mostly fatal. Improved survival can be achieved in selective patients with aggressive treatment. These improvements are confined to those without bone or bone marrow metastases. |
format | Text |
id | pubmed-1698143 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-16981432007-01-17 Improving Outcomes After Relapse in Ewing's Sarcoma: Analysis of 114 Patients From a Single Institution McTiernan, Anne M. Cassoni, Anna M. Driver, Deirdre Michelagnoli, Maria P. Kilby, Anne M. Whelan, Jeremy S. Sarcoma Clinical Study The outcome for patients with relapsed Ewing's sarcoma is poor. A retrospective analysis was carried out to identify factors associated with improved survival. Between 1992 and 2002, 114 patients presented with relapsed or progressive disease. Median time to progression/relapse was 13 months (range, 2–128). Treatment at relapse included high dose treatment (HDT) in 29 patients, and surgery or definitive radiotherapy in 29. 2 and 5-year post relapse survival (PRS) was 23.5% and 15.2%, respectively. In multivariate analysis, the most significant factors associated with improved survival were disease confined locally or to the lungs (2-year PRS, 40% versus 6%; P < .001), relapse > 18 months from diagnosis (2-year PRS, 53% versus 8%; P < .001), HDT at relapse (2-year PRS, 62% versus 11%; P < .001), and surgery and/or radiotherapy at relapse (2-year PRS, 51% versus 14%; P < .001). First treatment failure in Ewing's sarcoma is mostly fatal. Improved survival can be achieved in selective patients with aggressive treatment. These improvements are confined to those without bone or bone marrow metastases. Hindawi Publishing Corporation 2006 2006-11-06 /pmc/articles/PMC1698143/ /pubmed/17496997 http://dx.doi.org/10.1155/SRCM/2006/83548 Text en Copyright © 2006 Anne M. McTiernan et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study McTiernan, Anne M. Cassoni, Anna M. Driver, Deirdre Michelagnoli, Maria P. Kilby, Anne M. Whelan, Jeremy S. Improving Outcomes After Relapse in Ewing's Sarcoma: Analysis of 114 Patients From a Single Institution |
title | Improving Outcomes After Relapse in Ewing's Sarcoma: Analysis of 114 Patients From a Single Institution |
title_full | Improving Outcomes After Relapse in Ewing's Sarcoma: Analysis of 114 Patients From a Single Institution |
title_fullStr | Improving Outcomes After Relapse in Ewing's Sarcoma: Analysis of 114 Patients From a Single Institution |
title_full_unstemmed | Improving Outcomes After Relapse in Ewing's Sarcoma: Analysis of 114 Patients From a Single Institution |
title_short | Improving Outcomes After Relapse in Ewing's Sarcoma: Analysis of 114 Patients From a Single Institution |
title_sort | improving outcomes after relapse in ewing's sarcoma: analysis of 114 patients from a single institution |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1698143/ https://www.ncbi.nlm.nih.gov/pubmed/17496997 http://dx.doi.org/10.1155/SRCM/2006/83548 |
work_keys_str_mv | AT mctiernanannem improvingoutcomesafterrelapseinewingssarcomaanalysisof114patientsfromasingleinstitution AT cassoniannam improvingoutcomesafterrelapseinewingssarcomaanalysisof114patientsfromasingleinstitution AT driverdeirdre improvingoutcomesafterrelapseinewingssarcomaanalysisof114patientsfromasingleinstitution AT michelagnolimariap improvingoutcomesafterrelapseinewingssarcomaanalysisof114patientsfromasingleinstitution AT kilbyannem improvingoutcomesafterrelapseinewingssarcomaanalysisof114patientsfromasingleinstitution AT whelanjeremys improvingoutcomesafterrelapseinewingssarcomaanalysisof114patientsfromasingleinstitution |